H.C. Wainwright reiterated a Buy rating and $5.00 price target on MindWalk Holdings (NASDAQ:HYFT), representing nearly 300% upside from the current price of $1.26. The stock has already gained 157% over the past year.
On May 18, MindWalk released a report highlighting over 20 partner-owned drug candidates from its antibody discovery platform in oncology, immunology, neurology, and infectious disease. The platform has produced nine biologics in ten active clinical programs, four of which are first-in-class.
H.C. Wainwright views the disclosure as validation of the platform. MindWalk retains no downstream economics, but the firm expects meaningful transactions in the next 12-18 months.
The company maintains a strong balance sheet with more cash than debt and a current ratio of 3.74. In Q3 fiscal 2026, MindWalk reported revenues of $4.2 million, up 52% year-over-year.
